| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Inno-Gene S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł1.79 |
| 52 Week High | zł6.10 |
| 52 Week Low | zł1.65 |
| Beta | 1.14 |
| 1 Month Change | -8.21% |
| 3 Month Change | -36.75% |
| 1 Year Change | -69.03% |
| 3 Year Change | n/a |
| 5 Year Change | -4.79% |
| Change since IPO | -58.37% |
Recent News & Updates
Recent updates
Here's Why We Think Inno-Gene (WSE:IGN) Might Deserve Your Attention Today
Jul 25
Here's Why We Think Inno-Gene (WSE:IGN) Is Well Worth Watching
Apr 05Here's Why I Think Inno-Gene (WSE:IGN) Is An Interesting Stock
Dec 28Should You Be Adding Inno-Gene (WSE:IGN) To Your Watchlist Today?
Aug 28We Wouldn't Rely On Inno-Gene's (WSE:IGN) Statutory Earnings As A Guide
Feb 17
Shareholder Returns
| IGN | PL Life Sciences | PL Market | |
|---|---|---|---|
| 7D | -0.6% | 0.008% | 2.9% |
| 1Y | -69.0% | -11.8% | 28.3% |
Return vs Industry: IGN underperformed the Polish Life Sciences industry which returned -10.1% over the past year.
Return vs Market: IGN underperformed the Polish Market which returned 27% over the past year.
Price Volatility
| IGN volatility | |
|---|---|
| IGN Average Weekly Movement | 7.7% |
| Life Sciences Industry Average Movement | 6.1% |
| Market Average Movement | 5.2% |
| 10% most volatile stocks in PL Market | 9.5% |
| 10% least volatile stocks in PL Market | 3.2% |
Stable Share Price: IGN's share price has been volatile over the past 3 months.
Volatility Over Time: IGN's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 10 | Jacek Wojciechowicz | www.inno-gene.pl |
Inno-Gene S.A. provides genetic diagnostic solutions in Poland. It is involved in the research and diagnostic center implementation; and the provision of technologies in the field of DNA analysis. The company also develops and implements diagnostic algorithm for prevention and personalization of treatment of HPV-dependent solid tumors.
Inno-Gene S.A. Fundamentals Summary
| IGN fundamental statistics | |
|---|---|
| Market cap | zł11.10m |
| Earnings (TTM) | -zł1.46m |
| Revenue (TTM) | zł1.13m |
9.8x
P/S Ratio-7.6x
P/E RatioIs IGN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IGN income statement (TTM) | |
|---|---|
| Revenue | zł1.13m |
| Cost of Revenue | zł685.00k |
| Gross Profit | zł443.00k |
| Other Expenses | zł1.90m |
| Earnings | -zł1.46m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | -0.24 |
| Gross Margin | 39.27% |
| Net Profit Margin | -129.34% |
| Debt/Equity Ratio | 3.8% |
How did IGN perform over the long term?
See historical performance and comparison